IRVINE, CA, and HERSTAL, BELGIUM – April 7, 2023 – MDxHealth SA (Nasdaq and Euronext Brussels: MDXH) (the "Company" or "mdxhealth"), a commercial-stage precision diagnostics company, announces today in accordance with Article 14 of the Belgian Act of May 2, 2007 on the disclosure of important participations in issuers of which shares are admitted to trading on a regulated market and regarding miscellaneous provisions (the "Belgian Transparency Act"), that it received the following notification.
The Company was notified that the number of shares with respect to which Valiance Asset Management Limited can exercise voting rights passively crossed below the threshold of 10% of the outstanding shares and voting rights of mdxhealth on February 7, 2023. Notably, it follows from the notification by Valiance Asset Management Limited, who notified alone, that an aggregate of 20,931,094 shares of mdxhealth, representing 7.96% of the 262,880,936 outstanding shares and voting rights of mdxhealth, is held through the following entities: Valiance Holdings Limited, being a Guernsey company within the Valiance corporate structure; Valiance Life Sciences Growth Investment Fund SICAV-SIF, being a Luxembourg fund with multiple external investors; and TopMDx Ltd, being an exempted closed-ended fund registered in British Virgin Islands with multiple external investors. The notification also stated that the investment manager, Valiance Asset Management Limited, which is not a controlled entity, can exercise the voting rights at its discretion for each of these 3 entities.